RxDoctor Payments Data

Michael Cole, MD

Family Medicine · Fort Smith, ARNPI 1710973649

Payments from drug & device makers

$6,370in general payments, 2019–2025

Across 434 payments — averaging $14.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$982
  • AstraZeneca$856
  • Novo Nordisk$618
  • Pfizer$543
  • Lilly USA, LLC$447
  • Amgen$322
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$6,370100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,370 in reported general payments places this provider in the 85th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$79,795
Medicare patients
167
Services billed
2,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$76,826
EliquisApixaban41$49,002
XareltoRivaroxaban47$31,090
MounjaroTirzepatide26$27,344
EntrestoSacubitril/Valsartan15$17,056
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$14,330
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,769
TrulicityDulaglutide11$10,207
LinzessLinaclotide17$10,180
Aimovig AutoinjectorErenumab-Aooe12$8,883
JanumetSitagliptin Phos/Metformin Hcl15$8,453
SymbicortBudesonide/Formoterol Fumarate34$7,614
Lurasidone Hcl11$5,343
Diclofenac Sodium94$5,053
Atorvastatin Calcium691$4,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$618$76,82682 claims
PfizerEliquis$543$49,00241 claims
Lilly USA, LLCMounjaro, Trulicity$447$37,55037 claims
Johnson & JohnsonXarelto$202$31,09047 claims
GSKTrelegy Ellipta$239$12,76912 claims
AbbVieLinzess$982$10,18017 claims
MerckJanumet$83$8,45315 claims
AstraZenecaSymbicort$856$7,61434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →